Recent guidelines from the CDC recommend gabapentinoids as first-line agents for neuropathic pain. But some clinicians may be prescribing these medications excessively for various types of acute, subacute, and chronic noncancer pain in an attempt to avoid opioids.
No takes yet. Share an insight, caveat, or question.
Goodman et al. (2017) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: